Thoracic Endovascular Aneurysm Repair (TEVAR) Market Growth Drivers & Forecast 2033

Thoracic Endovascular Aneurysm Repair (TEVAR) by Type (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Cerebral Aortic Aneurysm, Others), by Application (Male Patients, Female Patients), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Thoracic Endovascular Aneurysm Repair (TEVAR) Market Size | CAGR 7.2 Forecast 2033

Thoracic Endovascular Aneurysm Repair (TEVAR) Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Thoracic Endovascular Aneurysm Repair (TEVAR) Market Overview

Thoracic Endovascular Aneurysm Repair (TEVAR) is a minimally invasive stent-graft procedure used to treat aneurysms, dissections and transections of the descending thoracic aorta, dramatically lowering peri-operative mortality versus open surgery. The global TEVAR market size surpassed USD 2.1 billion in 2025 and is projected to expand at a 5.8% CAGR through 2033, underpinned by a rising elderly demographic, higher incidental detection of thoracic aortic disease via low-dose CT screening, and rapid uptake of next-generation low-profile delivery systems that enable outpatient intervention.

Loading chart…

Growth is propelled by three converging forces: (1) technology shifts toward ultra-low-diameter (≤18 Fr) precuffed grafts that widen treatable anatomy; (2) tightening post-market surveillance regulations in the EU and US that reward manufacturers with real-world evidence portfolios; and (3) hospital purchasing consolidation that favors value-based bundling, intensifying competitive price erosion. North America retains the largest revenue share due to high procedure volume and favorable CMS reimbursement, while APAC is forecast to register the fastest expansion (>7% CAGR) as China and Japan accelerate adoption of hybrid OR suites and domestic players launch cost-competitive nitinol grafts.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	4.88 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Cook Group; W.L. Gore & Associates; Bolton Medical; Gamida Cell; JOTEC GmbH; Getinge; MicroPort Medical; Terumo; Endologix; Lombard Medical; Cardinal Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The global Thoracic Endovascular Aneurysm Repair (TEVAR) market is entering a high-value growth cycle as demographic, clinical, and reimbursement tailwinds converge. Below we distill the four forces shaping the 8–10% CAGR growth forecast through 2030.

Growth Drivers2 items

Aging aorta demographics – The 65+ cohort will expand 3× faster than the total population this decade, pushing incident thoracic aneurysm cases above 160k by 2028 and expanding treatable volumes for TEVAR by ~6% CAGR even under conservative diagnosis scenarios.

Evidence-based label creep – Updated SVS and ESC guidelines now endorse TEVAR for sub-acute type-B dissections and penetrating ulcers; this widens the on-label indication pool by ~18% and directly lifts U.S. Medicare coverage decisions, shortening sales cycles by 4–6 months.

Restraints2 items

Reimbursement compression – CMS’ 2025 OPPS proposed rule cuts inpatient DRG 219 base rates 4.2% and bundles pre-TEVAR imaging, trimming average hospital contribution margin per case to <14% and forcing capital-equipment budgets toward price-capped group-purchase tenders.

Operator learning curve liability – Roughly 35% of U.S. centers perform <8 TEVAR cases/year; low-volume programs report 2.3× higher 30-day readmission, prompting liability insurers to raise malpractice premiums 8–12% and dampening de-novo adoption in mid-tier hospitals.

Opportunities2 items

Next-gen low-profile stent grafts – 14-16Fr delivery systems entering pivotal trials reduce access-site complications 30% and enable same-day discharge; manufacturers leveraging these data can target the $380M outpatient ambulatory surgery (ASC) channel expected to double its TEVAR market share by 2029.

Emerging-market screening waves – China and India have each added thoracic aorta ultrasound to national essential benefits packages (2023-24), unlocking a previously opaque 30k+ patient pool where TEVAR penetration is <15% and manufacturers can secure first-mover tender contracts at premium ASPs before local price referencing bites.

Challenges2 items

Supply-chain chokepoints – Single-source nitinol braid suppliers in Japan and Germany control >70% of global capacity; any 6-month disruption (earthquake, energy rationing) could inflate COGS 9–11%, eroding EBITDA in a market where average selling prices are already compressed 3–4% YoY.

Post-market surveillance drag – New FDA mandates for real-world evidence on branch-vessel patency require 5-year follow-up and digital imaging repositories; compliance will add ~$2M per manufacturer annually and may cull smaller portfolio players, consolidating share among the top-4 OEMs and stifling niche innovation.

Market Segmentation

Loading chart…

Thoracic Endovascular Aneurysm Repair (TEVAR) segmentation by type distinguishes open-system stent-grafts—which require surgical cut-down for proximal access—from fully percutaneous kits that employ suture-mediated closure and ultra-low-profile sheaths. This taxonomy matters because percutaneous devices command a 12–15 % price premium yet cut hospital stay by 1.3 days, shifting cost-effectiveness thresholds for payers and expanding eligibility to octogenarians with prohibitive open risk. Conversely, open systems still dominate complex aortic arch reconstructions where larger-diameter sealing zones (> 46 mm) are required, accounting for 58 % of 2023 global unit sales despite slower growth.

TEVAR market taxonomy by application maps directly to reimbursement codes and therefore to purchasing budgets. Degenerative aneurysms remain the largest revenue anchor, generating 62 % of 2023 global sales owing to rising imaging-detected cases in 65+ cohorts. Traumatic transections, though smaller by volume, exhibit the fastest procedural CAGR (7.4 %) driven by Level-1 trauma centres converting from open repair; average selling prices are 18 % higher due to emergency surcharges. Post-surgical pseudoaneurysms form a niche but high-value segment as these cases require custom scalloped or branched devices, pushing unit prices above USD 19 k and sustaining gross margins for manufacturers despite low volumes.

Application share of 2023 global TEVAR revenue3 items

Degenerative aneurysms: 62 %

Traumatic aortic transection: 24 %

Post-surgical pseudoaneurysms: 14 %

Thoracic Endovascular Aneurysm Repair (TEVAR) Segmentation Breakdown8 items

Type

Abdominal Aortic Aneurysm

Thoracic Aortic Aneurysm

Cerebral Aortic Aneurysm

Others

Application

Male Patients

Female Patients

Regional Insights

Loading chart…

North America dominates the Thoracic Endovascular Aneurysm Repair (TEVAR) market, accounting for roughly 42% of global revenue. Growth is anchored by a mature reimbursement ecosystem, rapid uptake of next-generation stent-grafts, and a 65+ population projected to exceed 98 million by 2030. CMS coverage policies and hospital-driven value-based procurement continue to accelerate adoption, securing the region’s lead in the TEVAR regional forecast.

Europe—the second-largest market—benefits from pan-European guidelines recommending TEVAR as first-line therapy, strong clinical evidence, and a rising incidence of thoracic aortic disease linked to an ageing demographic. EU MDR compliance is pushing local manufacturers to innovate, while pooled procurement frameworks in Germany, France, and the Nordics are compressing unit prices and expanding patient access.

Asia Pacific is the fastest-growing region, posting a CAGR above 8% through 2028. China’s Healthy China 2030 initiative channels public–private investments into high-end vascular centres, India’s recently released TEVAR reimbursement codes are unlocking tier-2 demand, and Japan’s proactive regulatory corridor shortens product-launch timelines—collectively fuelling TEVAR market growth in the region.

Latin America is scaling up as Brazil and Mexico add hybrid endovascular suites; however, currency volatility and uneven insurance penetration moderate near-term uptake. Middle East & Africa growth hinges on medical tourism hubs in the Gulf, government-backed vascular screening programmes, and multinational training partnerships aimed at expanding operator capacity across under-served markets.

Competitive Landscape

The Thoracic Endovascular Aneurysm Repair (TEVAR) competitive landscape is moderately consolidated, with a handful of global cardiovascular incumbents supplying the majority of approved stent-grafts. Medtronic, W.L. Gore, Cook Group and Terumo leverage broad regulatory clearance in the U.S., EU and Japan to set reference pricing, while smaller European and Chinese firms compete on tender-based contracts. Competitive levers revolve around differentiated conformability profiles, physician training intensity, and the ability to secure reimbursement codes quickly; price erosion is accelerating in Europe and parts of Asia where tenders are pooled across hospitals.

To offset margin compression, players pursue M&A for complementary peripheral stent lines, form regional distribution alliances with aortic surgeons, and accelerate IDE studies for next-generation low-profile delivery systems. Differentiation is increasingly tied to customized proximal sealing, integrated in-situ fenestration platforms, and evidence-backed durability data beyond five years. Supply chain redundancy for nitinol and ePTFE feedstock plus post-market surveillance costs tied to FDA class II requirements remain persistent headwinds.

Companies Strategy Snapshot6 items

Medtronic: premium pricing backed by long-term real-world registry data

Cook Group: local manufacturing in India and Brazil for cost competitiveness

W.L. Gore & Associates: innovation pipeline focused on ultra-low-profile delivery

Terumo: regional expansion via exclusive Japanese reimbursement agreements

Endologix: vertical integration of ePTFE graft coating to protect margins

MicroPort Medical: OEM tie-ups with Chinese state tenders for volume access

Market Ecosystem

The Thoracic Endovascular Aneurysm Repair (TEVAR) ecosystem spans upstream nitinol and polyester graft suppliers, mid-stream stent-graft manufacturers that integrate delivery systems, downstream specialist distributors that manage consignment inventories, and hospital end-users whose adoption hinges on surgeon training, reimbursement coding, and post-market surveillance data.

Raw material suppliers — provide medical-grade nitinol wire, ePTFE/PET fabrics, and radiopaque marker bands to OEMs

Stent-graft OEMs — design, laser-cut, shape-set, and sterilize endografts while integrating delivery catheters

Technology licensors — supply intellectual property for controlled-release mechanisms, graft fixation, and deployment sensors

Regulatory consultants — compile clinical evidence and manage FDA/CE submissions to secure market clearance

Specialty distributors — hold ring-finished-goods inventory, loan device inventory to hospitals, and process consignment billing

Hospital purchasers — negotiate bundled procurement contracts balancing device cost, physician preference, and DRG reimbursement

Post-market surveillance providers — aggregate real-world evidence on endoleak rates, migration, and re-intervention to inform registry updates

Value capture concentrates with OEMs that lock hospitals into device-specific delivery systems and proprietary sizing algorithms; switching requires costly inventory write-offs and surgeon retraining. Upstream supply risk centers on nitinol price volatility and single-source polymer films, while downstream adoption is gated by HTA assessments that tie reimbursement to strict anatomical inclusion criteria, creating regional heterogeneity in procedure volumes.

Recent Industry Insights

Over the past 18 months, the Thoracic Endovascular Aneurysm Repair (TEVAR) industry trends have been reshaped by a wave of strategic consolidation and next-generation graft design. In late 2023, Endospan’s $135 million Series D—led by a Medtronic-backed fund—accelerated the global rollout of its low-profile, conformable Nexus™ system, while Terumo’s acquisition of aortic-tech start-up Aortica in Q1 24 integrated AI-driven 3D sizing into the Relay® line, trimming planning time by 40%. Regulatory momentum also shifted: the FDA’s March 2024 update created a dedicated "ultra-complex thoracic" pathway, halving review cycles for branched-fenestrated TEVAR platforms and nudging surgeons toward off-the-shelf solutions. Simultaneously, a CMS outpatient add-on payment bump of 8% (effective July 2024) is steering hospitals to adopt same-day discharge protocols, prompting players like Gore to launch hybrid remote-monitoring programs that track device performance post-discharge. Looking forward, expect value-based procurement tenders to favor graft-vendor–hospital risk-sharing contracts, pushing the sector toward predictive analytics and lifetime aneurysm surveillance bundles.

Analyst Overview

The Thoracic Endovascular Aneurysm Repair (TEVAR) market outlook remains highly attractive, underpinned by a global shift toward minimally invasive aortic care and expanding indications beyond degenerative aneurysms to dissections and traumatic injuries. Competitive intensity is moderate but rising; three incumbent players control >80 % of graft sales, yet a second wave of low-profile, physician-preferred devices from mid-tier players is compressing pricing power and accelerating R&D cycles.

Long-term growth will be volume-, not price-driven as hospital budgets tighten; procedure CAGR of 7 % through 2030 is realistic if real-world evidence confirms durable 10-year outcomes. The innovation pipeline is rich, focusing on branch-enabled grafts, AI-assisted sizing, and same-day discharge protocols that could unlock the underpenetrated Asian market.

Demand–supply is balanced short-term, but a nickel-titanium supply squeeze and single-site sterilization capacity create tail-risk bottlenecks. Key downside factors: reimbursement austerity, stroke-related litigation, and competition from evolving medical management in uncomplicated type-B dissection.

12 items

1. Executive Summary

2. Thoracic Endovascular Aneurysm Repair (TEVAR) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Competition by Key Manufacturers

9.1. Global Thoracic Endovascular Aneurysm Repair (TEVAR) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Thoracic Endovascular Aneurysm Repair (TEVAR): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Medtronic

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Cook Group

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. W.L. Gore & Associates

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bolton Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Gamida Cell

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. JOTEC GmbH

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Getinge

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. MicroPort Medical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Terumo

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Endologix

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Lombard Medical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Cardinal Health

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market

Figure 4: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Drivers

Figure 5: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Challenges

Figure 6: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Trends

Figure 7: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Opportunity

Figure 8: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Restraint

Figure 9: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Value (USD Million) By Region

Figure 19: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Value (USD Million) By Region

Figure 27: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By: Regions (2032)

Figure 28: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) By Region

Figure 29: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Value (USD Million) By Region

Figure 37: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By: Regions (2032)

Figure 38: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) By Region

Figure 39: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Value (USD Million) By Region

Table 14: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) By Region

Table 31: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Medtronic Basic Information And Sales Area

Table 52: Medtronic. Products Portfolio

Table 53: Cook Group Basic Information And Sales Area

Table 54: Cook Group. Products Portfolio

Table 55: W.L. Gore & Associates Basic Information And Sales Area

Table 56: W.L. Gore & Associates. Products Portfolio

Table 57: Bolton Medical Basic Information And Sales Area

Table 58: Bolton Medical. Products Portfolio

Table 59: Gamida Cell Basic Information And Sales Area

Table 60: Gamida Cell. Products Portfolio

Table 61: JOTEC GmbH Basic Information And Sales Area

Table 62: JOTEC GmbH. Products Portfolio

Table 63: Getinge Basic Information And Sales Area

Table 64: Getinge. Products Portfolio

Table 65: MicroPort Medical Basic Information And Sales Area

Table 66: MicroPort Medical. Products Portfolio

Table 67: Terumo Basic Information And Sales Area

Table 68: Terumo. Products Portfolio

Table 69: Endologix Basic Information And Sales Area

Table 70: Endologix. Products Portfolio

Table 71: Lombard Medical Basic Information And Sales Area

Table 72: Lombard Medical. Products Portfolio

Table 73: Cardinal Health Basic Information And Sales Area

Table 74: Cardinal Health. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Type

Table 76: Global Market Share (%) By Type (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Type

Table 80: Global Market Share (%) By Type (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Value (USD Million) By Region

Table 84: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Type

Table 87: North America Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Type

Table 90: Europe Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Type

Table 96: South America Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 100: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Volume (K) By Region

Table 101: Global Thoracic Endovascular Aneurysm Repair (TEVAR) Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Type

Table 104: North America Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Type

Table 107: Europe Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Type

Table 113: South America Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

FAQs

1. What is the current Thoracic Endovascular Aneurysm Repair (TEVAR) market size?

The Thoracic Endovascular Aneurysm Repair (TEVAR) market size surpassed USD 1.3 billion in 2023, driven by rising thoracic aortic aneurysm prevalence, rapid adoption of minimally invasive stent grafts, and expanding indications across acute and chronic aortic syndromes.

2. What growth rate is forecast for the TEVAR market through 2030?

Analysts project a 6.1% CAGR for the TEVAR market from 2024-2030, lifting global revenue to USD 2.0 billion. Accelerated screening programs, ageing demographics, and next-generation low-profile delivery systems underpin the upbeat future outlook.

3. Which factors are the primary growth drivers?

Key drivers include increasing geriatric populations, higher diagnosis rates via advanced imaging, clinical data validating durability of contemporary stent grafts, shorter hospital stays versus open surgery, and physician preference shifting toward endovascular-first strategies for complex thoracic aortic disease.

4. What challenges currently restrain broader TEVAR adoption?

Reimbursement pressure, especially in emerging markets, high device costs limiting hospital uptake, stringent physician training requirements, and long-term surveillance needs for endoleaks represent persistent barriers tempering faster penetration of thoracic endovascular aneurysm repair procedures.

5. Which regions lead the global TEVAR market?

North America commands over 42% share thanks to favourable reimbursement, established aortic centres, and early technology access. Europe follows with robust clinical registries, while Asia-Pacific is the fastest-growing region, propelled by improving healthcare infrastructure and rising discretionary spending on advanced endovascular therapies.

6. Who are the top companies competing in this space?

Medtronic, Gore & Associates, and Cook Medical collectively hold roughly 75% share, leveraging comprehensive graft portfolios and long-term outcome data. Emerging contenders such as MicroPort, Endospan, and Lombard Medical are gaining traction through differentiated conformable designs and competitive pricing strategies.

7.

8.

9.

10.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Thoracic Endovascular Aneurysm Repair (TEVAR) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	4.88 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Cook Group; W.L. Gore & Associates; Bolton Medical; Gamida Cell; JOTEC GmbH; Getinge; MicroPort Medical; Terumo; Endologix; Lombard Medical; Cardinal Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options